| Literature DB >> 22926720 |
German Matías Traglia1, Marisa Almuzara, Andrea Karina Merkier, Christina Adams, Laura Galanternik, Carlos Vay, Daniela Centrón, María Soledad Ramírez.
Abstract
In the last few years, numerous cases of multidrug-resistant Achromobacter xylosoxidans infections have been documented in immunocompromised and cystic fibrosis patients. To gain insights into the molecular mechanisms and mobile elements related to multidrug resistance in this bacterium, we studied 24 non-epidemiological A. xylosoxidans clinical isolates from Argentina. Specific primers for plasmids, transposons, insertion sequences, bla(ampC), intI1, and intI2 genes were used in PCR reactions. The obtained results showed the presence of wide host range IncP plasmids in ten isolates and a high dispersion of class 1 integrons (n = 10) and class 2 integrons (n = 3). Four arrays in the variable region (vr) of class 1 integrons were identified carrying different gene cassettes as the aminoglycoside resistance aac(6')-Ib and aadA1, the trimethoprim resistance dfrA1 and dfrA16, and the β-lactamase bla(OXA-2). In only one of the class 2 integrons, a vr was amplified that includes sat2-aadA1. The bla(ampC) gene was found in all isolates, confirming its ubiquitous nature. Our results show that A. xylosoxidans clinical isolates contain a rich variety of genetic elements commonly associated with resistance genes and their dissemination. This supports the hypothesis that A. xylosoxidans is becoming a reservoir of horizontal genetic transfer elements commonly involved in spreading antibiotic resistance.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22926720 PMCID: PMC3477587 DOI: 10.1007/s00284-012-0213-5
Source DB: PubMed Journal: Curr Microbiol ISSN: 0343-8651 Impact factor: 2.188
Characteristic and obtained results of the 24 A. xylosoxidans isolates used in the study
| Isolatea | Hospital | Year | Sourceb | IncP | IS26 | IS440 |
| vrc |
|
|---|---|---|---|---|---|---|---|---|---|
| Ax79 | Center 2 | 2004 | NP | + | − | + | + |
| + |
| Ax169 | Center 3 | 2004 | NP | + | − | + | + |
| + |
| Ax126 | Center 1 | 2001 | NP | + | + | − | + |
| + |
| Ax144 | Center 1 | 2001 | NP | + | − | + | − | NA | − |
| Ax69 | Center 2 | 2002 | CF | − | − | + | − | NA | − |
| Ax72 | Center 2 | 2007 | CF | + | − | − | + |
| − |
| Ax77 | Center 2 | 2007 | CF | − | − | + | − | NA | − |
| Ax210 | Center 3 | 2007 | CF | − | − | − | − | NA | − |
| Ax81 | Center 2 | 2008 | CF | − | − | − | − | NA | − |
| Ax82 | Center 2 | 2008 | CF | − | − | − | − | NA | − |
| Ax90 | Center 2 | 2008 | CF | − | − | − | − | NA | − |
| Ax91 | Center 2 | 2008 | CF | − | − | − | − | NA | − |
| Ax92 | Center 2 | 2008 | CF | − | − | − | − | NA | − |
| Ax93 | Center 2 | 2008 | CF | − | + | − | − | NA | − |
| Ax97 | Center 2 | 2007 | CF | − | − | − | − | NA | − |
| Ax336 | Center 2 | 2010 | CF | − | − | + | − | NA | − |
| Ax11 | Center 2 | 2004 | NP | − | − | − | + |
| − |
| Ax22 | Center 1 | 1995 | NP | − | − | − | − | NA | − |
| Ax44 | Center 1 | 2006 | NP | + | − | − | + |
| − |
| Ax56 | Center 1 | 2003 | NP | + | − | − | + |
| − |
| Ax68 | Center 6 | 2010 | NP | + | − | − | − | NA | − |
| Ax114 | Center 1 | 2002 | NP | + | − | − | + |
| − |
| Ax247 | Center 1 | 2006 | NP | − | − | + | − | NA | − |
| Ax304 | Center 4 | 1996 | NP | − | − | − | + |
| − |
| Ax2700 | Center 5 | 2006 | NP | + | − | − | − | NA | − |
NA not applicable
aIsolates of the study: Ax for Achromobacter xylosoxidans
bNP for nosocomial patient’s samples and CF for cystic fibrosis patient’s samples
cvr: class 1 integron variable region
Oligonucleotides used in the study
| Target | Oligonucleotide | Sequence 5′–3′ | References |
|---|---|---|---|
|
| TrwAB1 | AGCGTATGAAGCCCGTGAAGGG | [ |
| TrwAB2 | AAAGATAAGCGGCAGGACAATAACG | [ | |
|
| TrfA2 1 | CGAAATTCATATGGGAGAAGTA | [ |
| TrfA2 2 | CGTTTGCAATGCACCAGGTC | [ | |
|
| KikA1 | ACTTACCTTTATCAACATTCTGGCG | [ |
| KikA2 | CGACTGGTTACTTCCACCTTCGC | [ | |
|
| REPA | GGAGCGATTTGCATTCCG | [ |
| REPC | AAATGAGCCTGTTTGAG | [ | |
|
| CA1 | ATGTCGCAGACAGAAAATGC | [ |
| OR1 | CCTTGCAGTTTAATGTGAATAA | [ | |
| IS26 | IS26F | GCTGGCTGAACGCGGAG | [ |
| IS26R | ATACCTTTGATGGTGGC | [ | |
| IS440 | IS440F | CTCACTGTTCGCGACT | [ |
| IS440R | GGCATGCGCAGTGAGCGG | [ | |
| Tn1331 | Tn1331NF | GAATTGCCTCGTGATACGCCTATTT | [ |
| Tn1331NR | GCGGCCGCGATAGTTTGGCTGTGAGC AATT | [ | |
| Tn3 | Tn3F | AAGTTCATCGGGTTCGC | [ |
| 201L | ACTACGATACGGGAGGGCT | [ | |
|
| TnsAF | CTCCATATTCACTACTTGGCT | [ |
| TnsAR | GCTAACAGTACAAGAAGTTCC | [ | |
|
| TnsBF | CATGTGGTCCAAGAACATAAG | [ |
| TnsBR | GAGCAAGCATTTACAAAAGC | [ | |
|
| TnsCF | GTTTATCGTGATACGGGGG | [ |
| TnsCR | GCTATCCCAGTCGCTGGG | [ | |
|
| TnsDF | GGGATTGTTAGTCCTAAGC | [ |
| TnsDR | CCGTCTAATTTGATAATCTTC | [ | |
|
| TnsEF | TTGCTCTCTAACCACTCT | [ |
| TnsER | TCGATTTGCTGCTTTTGATG | [ | |
|
| aac(6)’ibF | TGTGACGGAATCGTTGC | [ |
| aac(6)’IbR | CAGTGACGGTTATTCCGC | [ | |
|
| Inti1F | CGAGGCATAGACTGTAC | [ |
| Inti1R | TTCGAATGTCGTAACCGC | [ | |
|
| Inti2F | GCAAATGAAGTGCAACGC | [ |
| Inti2R | ACACGCTTGCTAACGATG | [ | |
| 5 | Sulpro | GCCTGACGATGCGTGGA | [ |
| 3 | 3′CS | AAGCAGACTTGACCTGATAG | [ |
|
| SatF | TGAGCAGGTGGCGGAAAC | [ |
| SatR | TCATCCTGTGCTCCCGAG | [ | |
|
| aadA1r | TCATTGCGCTGCCATTC | [ |
| aadA1 | TCGATGACGCCAACTAC | [ | |
|
| Dhfr1r | CCTGAAATCCCCAGCAA | [ |
| dhfrA1 | AGCTGTTCACCTTTGGC | [ | |
|
| Oxa2F | GAAGAAACGCTACTCGC | [ |
| Oxa2R | TACCCACCAACCCATAC | [ | |
|
| Dhfr16F | CAAAGGCGAGCAACTTC | This study |
| Dhfr16R | CACCCTCATCATTCGTA | This study |
Fig. 1Schematic representation of arrays of class 1 integrons found among the A. xylosoxidans (n = 24) isolates. Thin black vertical closed bar The attI1 site, thin gray vertical closed bar the attC sites of the gene cassettes. Arrows The primers used to identify the class 1 integron vr. Figure is not in scale
Minimal inhibitory concentration (μg/ml) of integron positive strains
| Isolate | CAZ | FEP | PIP | IPM | MEM | AMK | GEN | TMP | CIP | vra |
|---|---|---|---|---|---|---|---|---|---|---|
| Ax79 | 8 | 32 | 0.25 | 1 | 0.125 | 128 | 128 | 0.25 | 8 |
|
| Ax169 | 32 | 128 | 0.25 | 0.5 | 0.5 | 128 | 128 | 1 | 16 |
|
| Ax126 | 4 | 32 | 0.5 | 1 | 0.25 | 128 | 128 | 0.125 | 16 |
|
| Ax72 | 4 | 32 | 0.25 | 1 | 0.25 | 256 | 256 | 4 | 6 |
|
| Ax11 | 32 | 128 | 8 | 4 | 0.24 | 128 | 128 | 64 | 64 |
|
| Ax44 | 16 | 32 | 0.5 | 1 | 0.5 | 128 | 128 | 256 | 4 |
|
| Ax56 | 8 | 32 | 8 | 2 | 0.06 | 64 | 32 | 0.125 | 2 |
|
| Ax114 | 16 | 32 | 0.125 | 1 | 0.125 | 128 | 128 | 0.125 | 16 |
|
| Ax304 | 32 | 128 | 8 | 4 | 0.125 | 128 | 128 | 32 | 4 |
|
CAZ ceftazidime, FEP cefepime, PIP piperacillin, IPM imipenem, MEM meropenem, AMK amikacin, GEN gentamicin, TMP trimethoprim-sulfamethoxazole, CIP ciprofloxacin
avr: class 1 integron variable region found in the Ax isolates